Resources for You
Tykerb (lapatinib) tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2010
- Tykerb is contraindicated in patients with known severe hypersensitivity (e.g., anaphylaxis) to this product or any of its components.
- Immune System Disorders: Hypersensitivity reactions including anaphylaxis
- Skin and Subcutaneous Tissue Disorders: Nail disorders including paronychia